| Literature DB >> 31530867 |
Tomasz Nowikiewicz1,2, Ewa Śrutek3, Iwona Głowacka-Mrotek4, Magdalena Tarkowska5, Agnieszka Żyromska6,7, Wojciech Zegarski3.
Abstract
Breast conserving treatment (BCT) is a safe standard therapeutic method in patients with early invasive breast cancer. However, it is associated with an increased risk of residual neoplastic tissues in surgical margins. The aim of this study was to assess the outcome of the use of the intraoperative pathologic analysis by the frozen section (FS) method for evaluation of the extent of the primary lumpectomy. The study concerns a retrospective analysis of a group of 1102 patients who underwent BCT between Jan 2015 and Dec 2016. The assessment focused on the frequency of the intraoperative pathologic analysis of the primary lumpectomy extent (fresh frozen section method). The influence of the BCT specimen analysis method on the free margins width, as well as the rate and the cause of reoperation were evaluated. The intraoperative lumpectomy evaluation was performed in 45.8% (505/1102) of patients (Group I), while in the remaining 54.2% of the cases it was decided to abandon this procedure (Group II). Although in 72 (14.3%) patients the intraoperative analysis gave negative results, the margins contained residual tumor tissue (vs. 16.9% in Group II). In Group I, conversion from the previously planned BCT to mastectomy was necessary in 5.9% (30/505) patients (vs. 9.7% in Group II). The duration of surgery was 48.9 ± 17.3 minutes (Group I) and 42.9 ± 13.6 minutes (Group II). In patients undergoing BCT, the use of the intraoperative pathologic analysis by the FS method resulted in a reduction of the total number of reoperations performed due to residual tumor found in the margins following the primary lumpectomy. However, it statistically significantly extended the duration of the surgery.Entities:
Mesh:
Year: 2019 PMID: 31530867 PMCID: PMC6748937 DOI: 10.1038/s41598-019-49951-y
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Studied group of patients.
Patients undergoing the procedure – clinical characteristics.
| Clinical data | Group I | Group II | P-value |
|---|---|---|---|
| (n = 505) | (n = 597) | ||
| # (%) | # (%) | ||
| Mean age (years) and range | 58.7 (25–85) | 59.4 (27–87) | 0.2421 |
| BMI (mean) | 27.08 ± 4.98 | 27.43 ± 5.08 | 0.2484 |
|
| |||
| invasive ductal | 446 (88.3%) | 513 (85.9%) | 0.2379 |
| invasive lobular | 42 (8.3%) | 64 (10.7%) | 0.1778 |
| invasive – other types | 17 (3.4%) | 20 (3.4%) | 0.9883 |
| Presence of DCIS | 164 (32.5%) | 221 (37.0%) | 0.1185 |
| Presence of | 11 (2.2%) | 13 (2.2%) | 0.9994 |
| Tumor multifocality | 81 (16.0%) | 113 (18.9%) | 0.2075 |
|
| |||
| T1 | 310 (61.4%) | 395 (66.2%) | 0.0981 |
| T2 | 191 (37.8%) | 190 (31.8%) | 0.0369 |
| T3 | 4 (0.8%) | 12 (2.0%) | 0.0968 |
| Palpable tumor mass | 357 (70.7%) | 370 (62.0%) | 0.0024 |
|
| |||
| G1 | 25 (5.0%) | 27 (4.5%) | 0.6968 |
| G2 | 352 (69.7%) | 445 (74.5%) | 0.076 |
| G3 | 107 (21.2%) | 100 (16.8%) | 0.0626 |
| nd | 21 (4.2%) | 25 (4.2%) | 0.9809 |
| ER positive | 428 (84.8%) | 498 (83.4%) | 0.5272 |
| PR positive | 385 (76.2%) | 433 (72.5%) | 0.1619 |
| HER2 positive | 62 (12.3%) | 73 (12.2%) | 0.9598 |
|
| |||
| luminal A | 316 (62.6%) | 377 (63.1%) | 0.7843 |
| luminal B HER2 negative | 67 (13.3%) | 74 (12.4%) | 0.656 |
| luminal B HER2 positive | 46 (9.1%) | 47 (7.9%) | 0.4755 |
| non-luminal HER2 positive | 16 (3.2%) | 26 (4.4%) | 0.3023 |
| triple negative | 60 (11.9%) | 73 (12.2%) | 0.8789 |
| Simultaneous axillary lymph node dissection | 54 (10.7%) | 39 (6.5%) | 0.0124 |
Results of a surgical margin analysis post initial breast sparing treatment.
| Clinical data | Group I | Group II | p |
|---|---|---|---|
| n = 505 (%) | n = 597 (%) | ||
| Negative margins (benign lesions) | 433 (85.7%) | 496 (83.1%) | 0.1189 |
| Positive margins | 72 (14.3%) | 101 (16.9%) | 0.2373 |
| - invasive cancer | 41/72 [56.9%] | 57/101 [56.4%] | |
| - DCIS | 28/72 [38.9%] | 40/101 [39.6%] | |
| - LCIS | 3/72 [4.2%] | 4/101 [4.0%] | |
| Cancer cells present in a specimen after reoperation | 35 (48.6%) | 58 (57.4%) | 0.0959 |
Patients participating in the trial – treatment results.
| Clinical data | Group I | Group II | P-value |
|---|---|---|---|
| (n=505) | (n=597) | ||
| # (%) | # (%) | ||
| Need for reoperation | 72 (14.3%) | 101 (16.9%) | 0.2373 |
| Need for mastectomy | 30 (5.9%) | 58 (9.7%) | 0.0202 |
|
| |||
| - within the range of 0–10 mm | 225 (44.6%) | 332 (55.6%) | 0.0028 |
| [mean] | [6.6 ± 4.7 mm] | [6.5 ± 4.6 mm] | 0.7219 |
| - 0 mm | 72 (14.3%) | 101 (16.9%) | |
| - 1 mm | 1 (0.2%) | 3 (0.5%) | |
| - 2–3 mm | 1 (0.2%) | 2 (0.3%) | |
| -4–5 mm | 5 (1.0%) | 19 (3.2%) | |
| - 6–10 mm | 146 (28.9%) | 207 (34.7%) | |
| over 10 mm | 280 (55.4%) | 265 (44.4%) | 0.0003 |
| Surgery duration [min] | 48.9 ± 17.3 | 42.9 ± 13.6 | <0.0001 |
Figure 2Patients qualified for the procedure – influence of an intraoperative analysis type on the positive margin rate.